ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1306

Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)

Giorgos Loizidis1, Nikhil Jiwrajka2, Colin Ligon3, Mary Porteous2 and Michael D. George4, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Internal Medicine, Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Connective tissue diseases, interstitial lung disease and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) has recently been defined to describe patients with interstitial lung disease (ILD) with certain clinical, serologic, and/or morphologic autoimmune characteristics who do not meet criteria for a specific CTD. It remains unclear, however, whether these patients have similar clinical presentations and prognoses to those with CTD-ILD. Our goal was to compare the characteristics of patients with IPAF to those with CTD-ILD, idiopathic pulmonary fibrosis (IPF), and IPF with positive autoantibodies.

Methods: We conducted a retrospective review of patients with ILD enrolled in a single-center, prospective pulmonary cohort from 2012-2017. All patients had undergone a comprehensive clinical, radiographic, and serologic evaluation with an ILD diagnosis established by a multidisciplinary panel including pulmonologists, a radiologist, and a pathologist. We reviewed medical records to collect additional information regarding patients’ rheumatologic history at the time of their initial presentation to our center and identified patients with either: a) IPAF (meeting ≥ 2 of the published clinical, serologic, or morphologic criteria), b) CTD-ILD (meeting established criteria for a CTD) c) IPF without autoantibodies, or d) IPF with autoantibodies (not meeting criteria for IPAF). We compared clinical characteristics, imaging findings, baseline pulmonary function tests (PFTs), and treatment patterns between patients with IPAF and each of the other groups.

Results: We identified 46 patients with IPAF, 117 with CTD (including 33 RA, 31 SSc, 30 DM/PM, 11 SS), 98 with IPF, and 37 with IPF with autoantibodies. IPAF and CTD-ILD patients were predominantly female and approximately 30% non-white, with similar rates of smoking, family history of autoimmunity, and baseline imaging characteristics (Table). Patients with IPF with or without antibodies were predominantly male and white, more likely to smoke, and less likely to have seen a rheumatologist. Baseline PFTs were similar across the groups. Treatment patterns during follow up were similar in patients with IPAF and CTD-ILD, with >50% receiving glucocorticoids and >30% receiving mycophenolate. A minority of patients with IPF with or without autoantibodies received glucocorticoids during follow-up and >25% of patients in both of these groups received pirfenidone.

Conclusion: Demographic and imaging characteristics were similar among patients with IPAF and CTD-ILD but quite different from those with IPF with or without autoantibodies, supporting the notion of a similar pathophysiology in IPAF and CTD-ILD. IPAF and CTD-ILD patients both commonly received immunosuppression; future work is needed to evaluate whether treatment response is similar in these populations and whether immunosuppression can benefit patients with IPF with positive autoantibodies.

Description: Macintosh HD:Users:George:Desktop:ILD:ACR ILD IPAF abstract 6.4.18 Table.png


Disclosure: G. Loizidis, None; N. Jiwrajka, None; C. Ligon, None; M. Porteous, None; M. D. George, Bristol Myers Squibb, 2.

To cite this abstract in AMA style:

Loizidis G, Jiwrajka N, Ligon C, Porteous M, George MD. Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-characteristics-and-treatment-patterns-in-patients-with-interstitial-pneumonia-with-autoimmune-features-ipaf/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-and-treatment-patterns-in-patients-with-interstitial-pneumonia-with-autoimmune-features-ipaf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology